NASDAQ:CPTS - Bayer Essure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Conceptus, Inc. designs, develops, markets and promotes solutions in women's healthcare. The Company's flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman's fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.

Receive CPTS News and Ratings via Email

Sign-up to receive the latest news and ratings for CPTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Current SymbolNASDAQ:CPTS
Previous Symbol
CUSIP20601610
Phone+1-302-6365400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Bayer Essure (NASDAQ:CPTS) Frequently Asked Questions

What is Bayer Essure's stock symbol?

Bayer Essure trades on the NASDAQ under the ticker symbol "CPTS."

Has Bayer Essure been receiving favorable news coverage?

Media stories about CPTS stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bayer Essure earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave media stories about the healthcare company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

How do I buy shares of Bayer Essure?

Shares of CPTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bayer Essure's official website?

The official website for Bayer Essure is http://www.conceptus.com/.

How can I contact Bayer Essure?

Bayer Essure's mailing address is 100 Bayer Rd, PITTSBURGH, PA 15205-9707, United States. The healthcare company can be reached via phone at +1-302-6365400.


MarketBeat Community Rating for Bayer Essure (NASDAQ CPTS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Bayer Essure and other stocks. Vote "Outperform" if you believe CPTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: Marijuana Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel